Table 3 Follow up CD4% and HIV-1 viral load after detecting major PI
From: It is time to consider third-line options in antiretroviral-experienced paediatric patients?
Patients who continued on an NNRTI regimen | CD4% range (mean CD4%); number (n) of patients | HIV-1 VL range (geometric mean of detectableVL) in IU/ml; number (n) of patients |
|---|---|---|
Baseline* | 19.9 - 49.6 (32.2); n = 5 | 2300-47,000 (15,804); n = 5 |
First follow up | 23.2-39.7 (30.8); n = 5 | 9400-25,000 (14,397); n = 5 |
Second follow up | 22.9-46.4 (32.4); n = 5 | 700-38,000 (5504); n = 4 |
Patients who continued on an LPV/r regimen | Â | Â |
Baseline* | 29.4-39.9 (34.6); n = 5 | 1000-34,000 (3898); n = 6 |
First follow up | 25.6-36.6 (32.4); n = 5 | 1 × LDL, remainder 1800-38,000 (7473); n = 6 |
Second follow up | 27.2-40.8 (35.6); n = 5 | 1 × LDL, remainder 320-390 (355); n = 5 |
Total: All patients | Â | Â |
Baseline* | 17.1-49.6 (31.9); n = 11 | 1000-47,000 (6450); n = 12 |
First follow up | 23.2-39.7 (31.4); n = 11 | 1 × LDL, remainder 1800-38,000 (9558); n = 11 |
Second follow up | 22.9-46.4 (33.1); n = 11 | 1 × LDL, remainder 320-38,000 (1794); n = 9 |